Daraxonrasib - (RASolute 305)

June 23, 2026: Revolution Medicines announced it has begun treating patients in RASolute 305 (NCT07621718), a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating zoldonrasib (RMC-9805), an oral RAS(ON) G12D-selective covalent inhibitor, in combination with standard-of-care chemotherapy as first-line treatment for previously untreated metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). The study compares zoldonrasib + investigator’s choice of modified FOLFIRINOX or gemcitabine/nab-paclitaxel versus placebo + chemotherapy. Primary endpoints are progression-free survival and overall survival; key secondary endpoints include additional antitumor activity measures, safety/tolerability, and patient-reported outcomes.

The company also referenced prior reported results that daraxonrasib (RMC-6236), its RAS(ON) multi-selective inhibitor, improved overall survival, progression-free survival, response rates, and quality-of-life measures versus standard-of-care chemotherapy in second-line metastatic pancreatic cancer across RAS genotypes, and noted an ongoing separate Phase 3 first-line pancreatic cancer trial (RASolute 303) evaluating daraxonrasib.